^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Portrait HER2 assay

    Company:
    ANGLE
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    8ms
    Parsortix system and assays being showcased at a leading European Breast Cancer Conference (ANGLE plc Press Release)
    "ANGLE plc...is pleased to announce its participation at the 14th European Breast Cancer Conference (EBCC) being held in Milan, Italy on 20 to 22 March 2024...ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay"
    Clinical data
    |
    Parsortix Liquid Biopsy • Portrait HER2 assay
    9ms
    Development and analytical validation of a novel assay for HER2 assessment on circulating tumor cells using Parsortix® isolation and BioView imaging technologies (AACR 2024)
    The assay enables the identification of both HER2 protein and gene copy information from each target cell with minimal cell loss, with the potential for minimally invasive patient monitoring during treatment and better classification of patients who may qualify and benefit from HER2-targeted therapies. An added value of the assay is the practicality of utilizing preserved blood samples, allowing streamline batch shipping of clinical samples.
    Circulating tumor cells • Tumor cell
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 negative • HER-2 expression
    |
    Parsortix Liquid Biopsy • Portrait HER2 assay